Resistance to antibiotics: are we in the post-antibiotic era?

Serious infections caused by bacteria that have become resistant to commonly used antibiotics have become a major global healthcare problem in the 21st century. They not only are more severe and require longer and more complex treatments, but they are also significantly more expensive to diagnose and to treat. Antibiotic resistance, initially a problem of the hospital setting associated with an increased number of hospital-acquired infections usually in critically ill and immunosuppressed patients, has now extended into the community causing severe infections difficult to diagnose and treat. The molecular mechanisms by which bacteria have become resistant to antibiotics are diverse and complex. Bacteria have developed resistance to all different classes of antibiotics discovered to date. The most frequent type of resistance is acquired and transmitted horizontally via the conjugation of a plasmid. In recent times new mechanisms of resistance have resulted in the simultaneous development of resistance to several antibiotic classes creating very dangerous multidrug-resistant (MDR) bacterial strains, some also known as "superbugs". The indiscriminate and inappropriate use of antibiotics in outpatient clinics, hospitalized patients and in the food industry is the single largest factor leading to antibiotic resistance. In recent years, the number of new antibiotics licensed for human use in different parts of the world has been lower than in the recent past. In addition, there has been less innovation in the field of antimicrobial discovery research and development. The pharmaceutical industry, large academic institutions or the government are not investing the necessary resources to produce the next generation of newer safe and effective antimicrobial drugs. In many cases, large pharmaceutical companies have terminated their anti-infective research programs altogether due to economic reasons. The potential negative consequences of all these events are relevant because they put society at risk for the spread of potentially serious MDR bacterial infections.

[1]  B. Robinson-Dunn,et al.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. , 1999, The New England journal of medicine.

[2]  M. Kollef,et al.  Antibiotic Resistance in the Intensive Care Unit , 2001, Annals of Internal Medicine.

[3]  R. Wenzel,et al.  The antibiotic pipeline--challenges, costs, and values. , 2004, The New England journal of medicine.

[4]  S. Deresinski Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Polk,et al.  Antimicrobial use and bacterial resistance. , 2000, Current opinion in microbiology.

[6]  Livermore,et al.  Antimicrobials: better use, better drugs, or both? , 2000, Current Opinion in Microbiology.

[7]  P. Weller,et al.  Antiparasitic drugs. , 1996, The New England journal of medicine.

[8]  G. Jacoby,et al.  The new beta-lactamases. , 2005, The New England journal of medicine.

[9]  C. J. Thomson,et al.  Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges. , 2004, Current opinion in microbiology.

[10]  P. Fey,et al.  Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. , 2003, Drugs.

[11]  J. Williams,et al.  Antibiotic resistance in Haemophilus influenzae: epidemiology, mechanisms, and therapeutic possibilities. , 1986, Reviews of infectious diseases.

[12]  A. Pantosti,et al.  Antibiotic use: the crystal ball for predicting antibiotic resistance. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Picazo Management of the febrile neutropenic patient: a consensus conference. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  E. Wald,et al.  Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. , 2002, The New England journal of medicine.

[15]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[16]  B. Oppenheim The changing pattern of infection in neutropenic patients. , 1998, The Journal of antimicrobial chemotherapy.

[17]  G. Jacoby,et al.  Mechanisms of disease: The new β-lactamases , 2005 .

[18]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[19]  R. Hancock,et al.  Are we approaching the end of the antibiotic era , 1998 .

[20]  L. Saravolatz,et al.  Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. , 1982, Annals of internal medicine.

[21]  M. Cetron,et al.  The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. , 1995, The New England journal of medicine.

[22]  D G White,et al.  The isolation of antibiotic-resistant salmonella from retail ground meats. , 2001, The New England journal of medicine.

[23]  S. Projan,et al.  Why is big Pharma getting out of antibacterial drug discovery? , 2003, Current opinion in microbiology.

[24]  M. Jacobs Streptococcus pneumoniae: epidemiology and patterns of resistance. , 2004, The American journal of medicine.

[25]  R. Wunderink,et al.  Increasing threat of Gram-negative bacteria , 2001, Critical care medicine.

[26]  T. Perl,et al.  Vancomycin-resistant enterococci: a road map on how to prevent the emergence and transmission of antimicrobial resistance. , 2003, Chest.

[27]  H. Jaffe,et al.  Infections due to penicillinase-producing Neisseria gonorrhoeae in the United States: 1976-1980. , 1981, The Journal of infectious diseases.

[28]  J. Patterson,et al.  Antibiotic utilization: is there an effect on antimicrobial resistance? , 2001, Chest.

[29]  F. Lowy Staphylococcus aureus infections. , 2009, The New England journal of medicine.

[30]  D. Malone,et al.  Excessive antibiotic use for acute respiratory infections in the United States. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  M. Roberts,et al.  Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. , 1996, FEMS microbiology reviews.

[32]  P. Huovinen Macrolide-resistant group a streptococcus--now in the United States. , 2002, The New England journal of medicine.

[33]  P. Fey,et al.  Ceftriaxone-resistant salmonella infection acquired by a child from cattle. , 2000, The New England journal of medicine.

[34]  D. Guillemot,et al.  Antibiotic use in humans and bacterial resistance. , 1999, Current opinion in microbiology.

[35]  J. Versalovic,et al.  Three-year surveillance of community-acquired Staphylococcus aureus infections in children. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  S. Levy The antibiotic paradox : how the misuse of antibiotics destroys their curative powers , 2002 .

[37]  R. Leclercq,et al.  Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  Christopher Dye,et al.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 2001, The New England journal of medicine.

[39]  H. Morton,et al.  Staphylococcus aureus , 1948, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[40]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[41]  J. Jorgensen,et al.  Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  D. Melé 21 ST -CENTURY , 2007 .

[43]  G. Boivin,et al.  Human Cytomegalovirus Resistance to Antiviral Drugs , 2005, Antimicrobial Agents and Chemotherapy.

[44]  J. Butler,et al.  An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. , 1998, The New England journal of medicine.

[45]  S. Hori,et al.  Mechanisms of antimicrobial resistance , 1989 .

[46]  G. Jacoby,et al.  The New b -Lactamases , 2005 .

[47]  A. Tomasz,et al.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. , 1999, The New England journal of medicine.

[48]  J. Besser,et al.  Quinolone-ResistantCampylobacter jejuniInfections in Minnesota, 1992–1998 , 1999 .

[49]  H L Rieder,et al.  Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 1998, The New England journal of medicine.

[50]  I Lind,et al.  Epidemiology of antibiotic resistant Neisseria gonorrhoeae in industrialized and developing countries. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[51]  D. Monnet,et al.  Transient intestinal carriage after ingestion of antibiotic-resistant Enterococcus faecium from chicken and pork. , 2001, The New England journal of medicine.

[52]  C. Rammelkamp,et al.  Resistance of Staphylococcus aureus to the Action of Penicillin.∗ , 1942 .

[53]  H. Wegener The consequences for food safety of the use of fluoroquinolones in food animals. , 1999, The New England journal of medicine.

[54]  S. Polly The Antibiotic Paradox: How the Misuse of Antibiotics Destroys Their Curative Powers , 2002 .

[55]  Donald Morrison,et al.  Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone , 2005, The Lancet.

[56]  F. Lowy Antimicrobial resistance: the example of Staphylococcus aureus. , 2003, The Journal of clinical investigation.

[57]  J. Powers,et al.  Trends in antimicrobial drug development: implications for the future. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  D. Hooper Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  L Lasagna,et al.  Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.

[60]  T. File Streptococcus pneumoniae and community-acquired pneumonia: A cause for concern , 2004, The American Journal of Medicine Supplements.

[61]  D. Kontoyiannis,et al.  Perspectives for the management of febrile neutropenic patients with cancer in the 21st century , 2005, Cancer.

[62]  F. Waldvogel New resistance in Staphylococcus aureus. , 1999, The New England journal of medicine.

[63]  A. Tomasz The pneumococcus at the gates. , 1995, The New England journal of medicine.

[64]  A. Tomasz,et al.  The challenge of antibiotic resistant bacterial pathogens: the medical need, the market and prospects for new antimicrobial agents. , 2004, Current opinion in microbiology.

[65]  L. Rice,et al.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. , 2000, The New England journal of medicine.

[66]  T. Foster The Staphylococcus aureus "superbug". , 2004, The Journal of clinical investigation.

[67]  G. Amsden Pneumococcal resistance in perspective: how well are we combating it? , 2004, The Pediatric infectious disease journal.

[68]  K. Seme,et al.  The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. , 2001, The Journal of antimicrobial chemotherapy.

[69]  D. Shlaes,et al.  The United States Food and Drug Administration and the end of antibiotics. , 1935, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  P Huovinen,et al.  Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  O. Vanderkooi,et al.  Predicting antimicrobial resistance in invasive pneumococcal infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  D. Gilbert,et al.  Is there hope for the prevention of future antimicrobial shortages? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  M. Ghannoum,et al.  Mechanisms of fungal resistance: an overview. , 2002, Drugs.

[74]  F. Saulnier,et al.  First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit* , 2005, Critical care medicine.